Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study (Q47185917)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 December 2017

Language	Label	Description	Also known as
English	Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study	scientific article published on 20 December 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Vincent Lévy

22

0 references

Florence Nguyen-Khac

object named as

Florence Nguyen-Khac

10

0 references

Anne-Sophie Michallet

19

object named as

Anne-Sophie Michallet

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

author name string

Caroline Dartigeas

1

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Eric Van Den Neste

2

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Julie Léger

3

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Hervé Maisonneuve

4

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Christian Berthou

5

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Marie-Sarah Dilhuydy

6

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Sophie De Guibert

7

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Stéphane Leprêtre

8

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Marie C Béné

9

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Rémi Letestu

11

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Florence Cymbalista

12

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Philippe Rodon

13

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Thérèse Aurran-Schleinitz

14

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Jean-Pierre Vilque

15

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Olivier Tournilhac

16

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Béatrice Mahé

17

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Kamel Laribi

18

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Alain Delmer

20

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Pierre Feugier

21

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Roselyne Delépine

23

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Philippe Colombat

24

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Véronique Leblond

25

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

CLL 2007 SA investigators

26

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

French Innovative Leukemia Organization (FILO)

27

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

publication date

20 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

The Lancet. Haematology.

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent advances in therapy of chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative assessment of three different indices of multimorbidity for studies on health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930235-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2352-3026(17)30235-1

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/29275118

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47185917&oldid=2143906164"